<DOC>
	<DOCNO>NCT01221753</DOCNO>
	<brief_summary>In research study , investigator study whether reduce dose radiation give standard dos chemotherapy reduce side effect without compromise control cancer . An approved treatment squamous cell carcinoma head neck initial chemotherapy follow radiation chemotherapy together . This treatment effective many immediate long-term side effect . People squamous cell carcinoma head neck ( SSCHN ) relate infection human papillomavirus ( HPV ) show high response treatment along high cure rate . The investigator think reduce intensity treatment , may able reduce immediate long-term side effect may lead long term improvement quality life function .</brief_summary>
	<brief_title>Docetaxel/Cisplatin/5-Fluorouracil ( TPF ) Human Papillomavirus ( HPV ) Squamous Cell Carcinoma Study</brief_title>
	<detailed_description>OBJECTIVES : Primary To determine rate local-regional control 2 year Secondary To determine Progression Free Survival 2 5 year To determine Overall Survival 2 5 year To assess acute toxicity long term toxicity reduce radiation dose 2 5 year</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm squamous cell carcinoma oropharynx unknown primary HPV 16 positive determine ISH p16 positive determine IHC . Stage 3 4 disease without evidence distant metastasis At least one evaluable uni bidimensionally measurable lesion RECIST 1.1 criterion 18 year age old No previous surgery , radiation therapy chemotherapy SSCHN allow time study entry ECOG Performance Status 0 1 No active alcohol addiction Adequate bone marrow , hepatic renal function define protocol Women childbearing potential must negative pregnancy test within 7 day start treatment Exclusion Criteria Pregnant breast feed woman woman men childbearing potential willing use adequate contraception treatment least 3 month Previous current malignancy sit Symptomatic peripheral neuropathy grade 2 great Symptomatic alter hear great grade 2 Other serious illness medical condition Patients experience involuntary weight loss 25 % body weight 2 month precede study entry Concurrent treatment anticancer therapy Participation investigational trial within 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>SSCHN</keyword>
	<keyword>HPV</keyword>
	<keyword>IMRT</keyword>
</DOC>